Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04783181 · ClinicalTrials.gov registry record · Phase 1
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
A Phase 1 study of Congenital Adrenal Hyperplasia, sponsored by Adrenas Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 5
- Study locations
NCT04783181 is a Phase 1 study of Congenital Adrenal Hyperplasia that is active but no longer recruiting, run by Adrenas Therapeutics. The registered enrollment target is 8 participants, below the 101-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT04783181, a Phase 1 study of Congenital Adrenal Hyperplasia, is active but no longer recruiting, sponsored by Adrenas Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.
Conditions Studied
Interventions
- BIOLOGICAL AAV BBP-631
Study Locations (5)
Illinois
- Ann and Robert H. Lurie Children's Hospital of Chicago - Chicago
Maryland
- National Institutes of Health Clinical Center - Bethesda
Minnesota
- University of Minnesota - Minneapolis
North Carolina
- Lucas Research, Inc. - Morehead City
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04783181
The ClinicalTrials.gov registry entry for NCT04783181 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (92% lower). The listed sponsor is Adrenas Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which AAV BBP-631 is the first listed.
NCT04783181 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Maryland, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04783181 about?
NCT04783181 is a clinical study titled "A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)". This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.
What is the current status of trial NCT04783181?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-07-01. Estimated completion is 2029-02.
What conditions does trial NCT04783181 study?
This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia.
What interventions are being tested in trial NCT04783181?
The interventions under investigation include: AAV BBP-631 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04783181?
This trial is sponsored by Adrenas Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04783181 being conducted?
This trial has 5 study locations across Illinois, Maryland, Minnesota, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Adrenal Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
RECRUITING · Phase 1
-
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
COMPLETED · Phase 1
-
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
RECRUITING · Phase 3
-
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
RECRUITING · Phase 2
-
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.